Companies Dominating the Oligonucleotide API Landscape
- Ionis Pharmaceuticals, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Jazz Pharmaceuticals plc
- BIOGEN INC.
- Sarepta Therapeutics, Inc.
- Alnylam Pharmaceuticals, Inc.
- Corden Pharma International GmbH
- Nitto Denko Avecia, Inc.
- Merck KGaA
- Ajinomoto Co., Inc.
- Kaneka Eurogentec S.A.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of oligonucleotide API is evaluated at USD 2.79 billion.
The oligonucleotide API market size was over USD 2.4 billion in 2024 and is poised to exceed USD 8 billion by 2037, growing at over 9.7% CAGR during the forecast period i.e., between 2025-2037. Globally rising prevalence of cancer and neurodegenerative diseases, growth in percentage of API manufacturing facilities, and growing expenditures on healthcare throughout the world will boost the market growth.
North America industry is estimated to hold largest revenue share of 36% by 2037, attributed majorly to increased healthcare spending, along with enhanced healthcare facilities in the region.
The major players in the market are Ionis Pharmaceuticals, Inc, .Jazz Pharmaceuticals plc, BIOGEN INC., Sarepta Therapeutics, Inc., Alnylam Pharmaceuticals, Inc., Corden Pharma International GmbH, Nitto Denko Avecia, Inc., Merck KGaA, Ajinomoto Co., Inc., Kaneka Eurogentec S.A.
